Ulthera is a technology company.
Ulthera has raised $34.0M across 2 funding rounds.
Ulthera has raised $34.0M in total across 2 funding rounds.
Ulthera, Inc. (now operating as Ultherapy) is a medical device company that develops the Ulthera System, a therapeutic ultrasound platform for non-invasive aesthetic skin lifting treatments. The system targets aesthetic and medical applications, serving physicians and patients seeking alternatives to surgery by lifting skin on the brow, neck, under the chin, and improving décolleté lines and wrinkles through micro-focused ultrasound that stimulates collagen production.[1][4][5][6] It solves the problem of sagging skin in hard-to-treat areas without downtime, with Ultherapy PRIME offering enhanced speed (20% faster), ergonomic design, and proven results including 95% patient satisfaction at one year and over 3 million treatments worldwide.[4][5]
The company demonstrates strong growth momentum as the recognized gold standard in non-invasive lifting, backed by over 50 clinical studies, 120+ peer-reviewed papers, and awards like NewBeauty's "Best Nonsurgical Skin Tightener" for 11 years.[2][5] Originally a growth-stage private firm in Mesa, Arizona, it has evolved into a global leader available in 80+ countries.[1][5]
Founded in 2004 in Mesa, Arizona, Ulthera pioneered therapeutic ultrasound for aesthetics as a privately held company backed by venture firms like New Enterprise Associates and Apposite Capital.[1][2] The core innovation emerged from developing the Ulthera System—the first energy-based device with FDA clearance for non-invasive aesthetic lift, initially for brow, neck, and chin treatments.[1][2]
Early traction came from filling an unmet need for non-surgical skin tightening, with Ultherapy named "Best In-Office Treatment" by NewBeauty in 2013 under CEO Matthew Likens.[2] The company rebranded elements to Ultherapy (formerly known as Ulthera), expanding its platform while maintaining focus on ultrasound imaging-guided treatments.[3][4]
Ulthera rides the wave of non-invasive aesthetics, capitalizing on demand for zero-downtime procedures amid rising consumer preference for natural-looking results over surgery. Timing aligns with ultrasound tech maturation and FDA validations since 2004, enabling expansion from facial lifts to broader applications.[1][5] Market forces like aging populations, social media-driven beauty standards, and post-pandemic self-care trends favor its growth, with over 3 million treatments in 80 countries.[5]
It influences the ecosystem by setting the gold standard, inspiring competitors and elevating physician practices through reliable, evidence-backed tools that integrate into modern aesthetics workflows.[2][4][5]
Ultherapy PRIME positions Ulthera for continued dominance with software innovations, stability upgrades, and ergonomic edges that streamline high-volume practices. Expect expansion into new indications, global markets, and hybrid treatments combining ultrasound with other modalities as personalized aesthetics trends accelerate. Its unmatched clinical legacy and patient trust will likely sustain leadership, potentially through partnerships or acquisitions in the $15B+ medspa sector—reinforcing non-invasive tech as the future of skin rejuvenation, much like its original disruption of surgical lifts.
Ulthera has raised $34.0M in total across 2 funding rounds.
Ulthera's investors include Questa Capital, Vensana Capital.
Ulthera has raised $34.0M across 2 funding rounds. Most recently, it raised $11.0M Series C in February 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2011 | $11.0M Series C | Questa Capital, Vensana Capital | |
| Jan 1, 2008 | $23.0M Series B | Questa Capital, Vensana Capital |